Usefulness of retinoic acid in the treatment of melasma

M. A. Pathak, T. B. Fitzpatrick, E. W. Kraus

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Melasma is a circumscribed brown macular hypermelanosis of the areas of the face and neck that are exposed to light. Clinical trials with various depigmenting formulations containing hydroquinone were conducted to determine the ideal concentration of hydroquinone, retinoic acid, and corticosteroids for the treatment of melasma. The compounds were tested with and without the concomitant use of topical sunscreen preparations. Based on the results of the trials and our earlier clinical experience, we conclude that treatment of melasma should involve the following: avoidance of sun exposure, constant use of broad-spectrum sunscreens, and topical application of a cream or lotion containing 2% hydroquinone and 0.05% to 0.1% retinoic acid (tretinoin). Patients should suspend use of oral contraceptives and other agents that promote skin pigmentation. The monobenzyl ether of hydroquinone should never be used in melasma therapy.

Original languageEnglish (US)
Pages (from-to)894-899
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume15
Issue number4 II SUPPL.
StatePublished - 1986
Externally publishedYes

Fingerprint

Melanosis
Tretinoin
Sunscreening Agents
Skin Pigmentation
Hyperpigmentation
Solar System
Therapeutics
Oral Contraceptives
Contraceptive Agents
Adrenal Cortex Hormones
Neck
Clinical Trials
Light
hydroquinone

ASJC Scopus subject areas

  • Dermatology

Cite this

Pathak, M. A., Fitzpatrick, T. B., & Kraus, E. W. (1986). Usefulness of retinoic acid in the treatment of melasma. Journal of the American Academy of Dermatology, 15(4 II SUPPL.), 894-899.

Usefulness of retinoic acid in the treatment of melasma. / Pathak, M. A.; Fitzpatrick, T. B.; Kraus, E. W.

In: Journal of the American Academy of Dermatology, Vol. 15, No. 4 II SUPPL., 1986, p. 894-899.

Research output: Contribution to journalArticle

Pathak, MA, Fitzpatrick, TB & Kraus, EW 1986, 'Usefulness of retinoic acid in the treatment of melasma', Journal of the American Academy of Dermatology, vol. 15, no. 4 II SUPPL., pp. 894-899.
Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. Journal of the American Academy of Dermatology. 1986;15(4 II SUPPL.):894-899.
Pathak, M. A. ; Fitzpatrick, T. B. ; Kraus, E. W. / Usefulness of retinoic acid in the treatment of melasma. In: Journal of the American Academy of Dermatology. 1986 ; Vol. 15, No. 4 II SUPPL. pp. 894-899.
@article{abe152ce92da4e1bb7751f21fed556dd,
title = "Usefulness of retinoic acid in the treatment of melasma",
abstract = "Melasma is a circumscribed brown macular hypermelanosis of the areas of the face and neck that are exposed to light. Clinical trials with various depigmenting formulations containing hydroquinone were conducted to determine the ideal concentration of hydroquinone, retinoic acid, and corticosteroids for the treatment of melasma. The compounds were tested with and without the concomitant use of topical sunscreen preparations. Based on the results of the trials and our earlier clinical experience, we conclude that treatment of melasma should involve the following: avoidance of sun exposure, constant use of broad-spectrum sunscreens, and topical application of a cream or lotion containing 2{\%} hydroquinone and 0.05{\%} to 0.1{\%} retinoic acid (tretinoin). Patients should suspend use of oral contraceptives and other agents that promote skin pigmentation. The monobenzyl ether of hydroquinone should never be used in melasma therapy.",
author = "Pathak, {M. A.} and Fitzpatrick, {T. B.} and Kraus, {E. W.}",
year = "1986",
language = "English (US)",
volume = "15",
pages = "894--899",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4 II SUPPL.",

}

TY - JOUR

T1 - Usefulness of retinoic acid in the treatment of melasma

AU - Pathak, M. A.

AU - Fitzpatrick, T. B.

AU - Kraus, E. W.

PY - 1986

Y1 - 1986

N2 - Melasma is a circumscribed brown macular hypermelanosis of the areas of the face and neck that are exposed to light. Clinical trials with various depigmenting formulations containing hydroquinone were conducted to determine the ideal concentration of hydroquinone, retinoic acid, and corticosteroids for the treatment of melasma. The compounds were tested with and without the concomitant use of topical sunscreen preparations. Based on the results of the trials and our earlier clinical experience, we conclude that treatment of melasma should involve the following: avoidance of sun exposure, constant use of broad-spectrum sunscreens, and topical application of a cream or lotion containing 2% hydroquinone and 0.05% to 0.1% retinoic acid (tretinoin). Patients should suspend use of oral contraceptives and other agents that promote skin pigmentation. The monobenzyl ether of hydroquinone should never be used in melasma therapy.

AB - Melasma is a circumscribed brown macular hypermelanosis of the areas of the face and neck that are exposed to light. Clinical trials with various depigmenting formulations containing hydroquinone were conducted to determine the ideal concentration of hydroquinone, retinoic acid, and corticosteroids for the treatment of melasma. The compounds were tested with and without the concomitant use of topical sunscreen preparations. Based on the results of the trials and our earlier clinical experience, we conclude that treatment of melasma should involve the following: avoidance of sun exposure, constant use of broad-spectrum sunscreens, and topical application of a cream or lotion containing 2% hydroquinone and 0.05% to 0.1% retinoic acid (tretinoin). Patients should suspend use of oral contraceptives and other agents that promote skin pigmentation. The monobenzyl ether of hydroquinone should never be used in melasma therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022968259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022968259&partnerID=8YFLogxK

M3 - Article

C2 - 3534025

AN - SCOPUS:0022968259

VL - 15

SP - 894

EP - 899

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4 II SUPPL.

ER -